BioAtla, Inc. (BCAB) company profile
Close on Oct 19, 2026Market cap $2.18MP/E –Yield –
About BioAtla
Biological Products, (No Diagnostic Substances), SIC 2836
BioAtla is a clinical-stage biopharmaceutical company that discovers and engineers conditionally active antibody therapeutics for the treatment of solid tumor cancers. Utilizing its proprietary Conditionally Active Biologics platform, the company designs therapeutic candidates—including antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies—that selectively target cancer cells in acidic tumor microenvironments while sparing healthy tissues. Key pipeline assets include BA3182, an EpCAM- and CD3-targeting bispecific candidate evaluated in advanced adenocarcinoma, and ozuriftamab vedotin, a ROR2-directed antibody-drug conjugate studied in oropharyngeal squamous cell carcinoma. The firm aims to serve cancer patients by developing oncological therapies that reduce systemic toxicity and expand treatable target antigens.
The company operates without internal manufacturing facilities, outsourcing clinical trial drug supply, filling, packaging, storage, and distribution to third-party contract manufacturers. As of February 1, 2026, its intellectual property portfolio comprises 597 issued patents, 13 allowed applications, and 258 pending applications across multiple jurisdictions. The provided text does not identify headquarters or specific operating countries.
Summary of the business section of BioAtla's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BioAtla, Inc.
- Headquarters
- San Diego, CA
- Address
- 11085 Torreyana Road 92121
- Phone
- (858) 558-0708
- Website
- bioatla.com
- Employees
- 41, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Diego, California
Stock & identifiers
- Ticker
- BCAB
- Exchange
- OTC
- IPO date
- Dec 17, 2020
- Shares outstanding
- 2M, Aug 10, 2026
- Public float
- $18.70M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-50 reverse, Apr 6, 2026
- SEC CIK
- 1826892
- CUSIP
- 09077B203
- ISIN
- US09077B2034
- FIGI
- BBG00Y6GBT61
- Share class FIGI
- BBG00Y6GBV39
- EIN
- 85-1922320
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jay M. Short Phd | Chief Executive Officer, Director | 84,300 |
| Eric Sievers | Chief Medical Officer | 11,346 |
| Christian Vasquez | Chief Financial Officer | 10,476 |
| Richard A. Waldron | Former Chief Financial Officer | 343,421 |
| Eddie Williams | Director | 60,200 |
| Mary Ann Gray | Director | 77,397 |
| Scott Andrew Smith | Director | 321,550 |
| Susan Moran | Director | 52,307 |
| Lawrence Steinman | Director | 78,459 |
| Sylvia McBrinn | Director | 59,125 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $879.25K | $866.13K | $550.29K | $7 | – |
| FY2024 | $1.95M | $1.24M | $921.39K | $7 | – |
| FY2023 | $3.30M | $154.54K | $1.27M | $30 | – |
| FY2022 | $2.54M | -$3.09M | $1.15M | $42 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Total | vs. prior year |
|---|---|---|---|---|
| Jay M. Short, Ph.D. Chief Executive Officer, Co-founder, and Chairman of the Board of Directors | $734.82K | $144.43K | $879.25K | -55% |
| Richard A. Waldron Chief Financial Officer | $485.45K | $30.73K | $516.18K | -41% |
| Eric Sievers, M.D. Chief Medical Officer | $530.63K | $53.78K | $584.41K | -39% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Dec 17, 2020
- Offer price
- $18.00
- Securities offered
- 10,500,000
- Gross proceeds
- $189.00M
- Exchange
- Nasdaq
- First trading day
- Dec 16, 2020
- First-day close
- $31.02+72.3%
- Lock-up ends (est.)
- Jun 14, 2021
“The initial public offering price of our common stock is $18.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 41 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 28, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 11, 2026 | Merger vote | Definitive merger proxy statement |
| Feb 6, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 16, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 7, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Dec 17, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Dec 9, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?